Inozyme Pharma, Inc. (NASDAQ:INZY) Receives Average Recommendation of “Hold” from Brokerages

Shares of Inozyme Pharma, Inc. (NASDAQ:INZY) have been assigned a consensus rating of “Hold” from the nine analysts that are presently covering the company, MarketBeat.com reports. Five investment analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $11.75.

INZY has been the topic of a number of research reports. Raymond James Financial dropped their target price on shares of Inozyme Pharma from $24.00 to $12.00 and set an “outperform” rating on the stock in a research report on Wednesday, March 12th. Jefferies Financial Group restated a “hold” rating and issued a $4.00 price target (down from $15.00) on shares of Inozyme Pharma in a research report on Friday, May 16th. Piper Sandler dropped their price objective on shares of Inozyme Pharma from $30.00 to $23.00 and set an “overweight” rating on the stock in a report on Tuesday, March 11th. HC Wainwright reiterated a “buy” rating and issued a $16.00 target price on shares of Inozyme Pharma in a research note on Thursday, April 10th. Finally, Wedbush downgraded Inozyme Pharma from a “strong-buy” rating to a “hold” rating in a research report on Friday, May 16th.

Institutional Trading of Inozyme Pharma

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Raymond James Financial Inc. bought a new position in Inozyme Pharma during the fourth quarter worth about $205,000. Intech Investment Management LLC acquired a new position in shares of Inozyme Pharma in the 4th quarter worth approximately $68,000. American Century Companies Inc. lifted its position in shares of Inozyme Pharma by 11.6% during the 4th quarter. American Century Companies Inc. now owns 79,349 shares of the company’s stock worth $220,000 after buying an additional 8,263 shares during the period. JPMorgan Chase & Co. boosted its stake in Inozyme Pharma by 345.5% in the 4th quarter. JPMorgan Chase & Co. now owns 128,872 shares of the company’s stock valued at $357,000 after buying an additional 99,944 shares in the last quarter. Finally, BIT Capital GmbH acquired a new stake in Inozyme Pharma in the 4th quarter valued at $177,000. Institutional investors own 88.30% of the company’s stock.

Inozyme Pharma Price Performance

NASDAQ INZY opened at $4.00 on Friday. The stock has a 50-day simple moving average of $3.15 and a 200 day simple moving average of $2.07. Inozyme Pharma has a twelve month low of $0.72 and a twelve month high of $6.24. The stock has a market capitalization of $258.25 million, a PE ratio of -2.37 and a beta of 2.27. The company has a debt-to-equity ratio of 0.65, a quick ratio of 2.19 and a current ratio of 2.19.

Inozyme Pharma (NASDAQ:INZY) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.01). Research analysts anticipate that Inozyme Pharma will post -1.59 EPS for the current year.

About Inozyme Pharma

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.